» Articles » PMID: 12868557

Systemic Capillary Leak Syndrome Resulting from Gemcitabine Treatment in Renal Cell Carcinoma: a Case Report

Overview
Journal J Chemother
Date 2003 Jul 19
PMID 12868557
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

In a few cases, gemcitabine (GCB) has been shown to result in systemic capillary leak syndrome (SCLS) in the treatment of non-small cell lung, pancreatic, and ovarian carcinomas. SCLS is a life-threatening condition characterized by increased capillary permeability resulting in manifest pulmonary and peripheral edema. Usually SCLS responds successfully to corticosteroid therapy and diuretics. We present a case where GCB treatment likely resulted in SCLS in a male patient with metastatic renal cell carcinoma (RCC) in the absence of predisposing cardiac, pleural, or pulmonary disease.

Citing Articles

Systemic Capillary Leak Syndrome (SCLS) Presentation in Patients Receiving Anti-cancer Treatments.

Anipindi M, Kacarow J, Bitetto D Cureus. 2023; 15(4):e38335.

PMID: 37261188 PMC: 10228707. DOI: 10.7759/cureus.38335.


Anticancer Drug-Induced Capillary Leak Syndrome.

Izzedine H, Mathian A, Amoura Z, Ng J, Jhaveri K Kidney Int Rep. 2022; 7(5):945-953.

PMID: 35570987 PMC: 9091576. DOI: 10.1016/j.ekir.2022.02.014.


First line Immunotherapy for Non-Small Cell Lung Cancer.

Nasser N, Gorenberg M, Agbarya A Pharmaceuticals (Basel). 2020; 13(11).

PMID: 33171686 PMC: 7695295. DOI: 10.3390/ph13110373.


Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease.

Casadei Gardini A, Aquilina M, Oboldi D, Lucchesi A, Carloni S, Tenti E BMC Cancer. 2013; 13:542.

PMID: 24215543 PMC: 3840643. DOI: 10.1186/1471-2407-13-542.